JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy
  • Search
  • Contact Us
  • FDA Approves First Oral GLP-1 for Chronic Weight Management

  • FDA Approves Merilog, the First Rapid-Acting Insulin Biosimilar

  • FDA Approves Ozempic for Chronic Kidney Disease in Type 2 Diabetes

  • FDA Approves Wegovy for MASH Treatment

  • FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity

  • FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity

  • FDA Clears Omnipod 5 for Type 2 Diabetes Management

  • Lilly Prepares for High Demand With $550M Stockpile of Oral GLP-1

  • Sustained Weight Loss and Cardiovascular Risk Reduction with Wegovy

  • Teva Launches First Generic GLP-1 for Obesity

  • Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment

  • Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea

  • You are here:  
  • Home
  • Tags
  • FDA Approval
 

JCS/T2D

We are advocates. We learn. We share. We inform.
Bringing clarity to type 2 diabetes, obesity care, health research, and the data behind them.

Content is provided for educational and informational purposes and is not medical advice.

Helpful Links

About Us
Contact Us
JCS Analytics

Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.